Preview

Russian journal of hematology and transfusiology

Advanced search

BIOCHEMICAL PARAMETERS OF DONOR PLATELET CONCENTRATES DURING THE STORAGE AFTER PATHOGEN INACTIVATION WITH THE AID OF TECHNOLOGY “AMOTOSALEN + ULTRA-VIOLET A IRRADIATION” IN VITRO

https://doi.org/10.18821/0234-5730-2017-62-1-37-40

Abstract

Pathogen inactivation (PI) treatment of platelet concentrates (PCs) improves the transfusion safety. PI technology allows to store of PCs up to 7 days. The usage of platelet additive solution (PAS) reduces the risk of non-hemolytic transfusion reactions and enhances platelet quality during storage. The influence of the combinations of PI and PAS and PI and 100% plasma on the biochemical parameters of PCs remained unclear. The aim of the study was to analyze the impact PI technology on the biochemical parameters and functional activity of platelets suspended in 100% plasma or 70% PAS and 30% plasma. The pathogens reduction does not influence on the glucose consumption and citrate content, accelerates the accumulation of lactate and lowers the pH of the medium storage donor platelet concentrates. In the samples with additive solution SSP+ changes of biochemical parameters were expressed to a lesser degree.

About the Authors

M. Kh. Azimova
National Research Center for Hematology
Russian Federation
Moscow, 125167


G. M. Galstyan
National Research Center for Hematology
Russian Federation
Moscow, 125167


T. V. Gaponova
National Research Center for Hematology
Russian Federation
Moscow, 125167


A. V. Karyakin
National Research Center for Hematology
Russian Federation
Moscow, 125167


G. N. Kryukova
National Research Center for Hematology
Russian Federation
Moscow, 125167


S. S. Nekhaevskaya
National Research Center for Hematology
Russian Federation
Moscow, 125167


E. D. Skotselyas
National Research Center for Hematology
Russian Federation
Moscow, 125167


P. A. Flegontov
National Research Center for Hematology
Russian Federation
Moscow, 125167


References

1. Dodd R.Y. Will blood products be free of infectious agents? In: Nanse S.J., ed. Transfusion Medicine. Arlington; 1990: 223–51.

2. Savchenko V.G., Garmaeva T.Ts., Kulikov S.M., Filatov F.P., Sudarikov A.B., Mikhaylova E.A. The efficacy and safety of transfusion therapy of hematological diseases. Therapeutic archive. Russian Journal (Terapevticheskiy arhiv). 2006; 7: 12–8. (in Russian)

3. Bryant B.J., Klein H.G. Pathogen inactivation: the definitive safeguard for the blood supply. Arch. Pathol. Lab. Med. 2007; 131(5): 719–33.

4. Schmidt M., Korn K., Nubling C.M., Chudy M., Kress J., Horst H.A., et al. First transmission of human immunodeficiency virus type l by a cellular blood product after mandatory nucleic acid screening in Germany. Transfusion. 2009; 49(9): 1836–44.

5. Irsch J., Lin L. Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT Blood System™. Transfus. Med. Hemother. 2011; 38(1): 19–31.

6. Ahrens N. Transfusion – related immune reactions: phatogenesis and preventions. Vox Sang. 2009; 4(2): 230–5.

7. Shevchenko Yu.L., Zhiburt E.B. Safe blood transfusions: a guide for physicians. St.Peterburg: PITER; 2000. (in Russian)

8. Council of Europe. Guide to the preparation, use and Quality – Assurance of Blood Components. 17tn ed. Strasbourg: Council of Europe Press; 2013.

9. Dumont L.J., Cancelas J.A., Graminske S., Friedman K.D., Vassallo R.R., Whitley P.H., et al. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion. 2013; 53(5): 972–80. doi: 10.1111/j.1537-2995.2012.03841.x.

10. Hechler B., Ohlmann P., Chafey P., Ravanat C., Eckly A., Maurer E., et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion. 2013; 53(6): 1187–200. doi: 10.1111/j.1537-2995.2012.03923.x.

11. Bashir S., Cookson P., Wiltshire M., Hawkins L., Sonoda L., Thomas S., et el. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion. 2013; 53(5): 990–1000.

12. Sandgren P., Diedrich B. Pathogen inactivation of double-dose buffy-coat platelet concentrates photochemically treated with amotosalen and UVA light: preservation of in vitro function. Vox Sangunis. 2015; 108(4): 340–9, doi: 10.1111/vox.12232.

13. Shimizu T., Murphy S. Roles of acetate and phosphate in the successful storage of platelet concentrates prepared with an acetate-containing additive solution. Transfusion. 1993; 33(4): 304–10.

14. Gulliksson H., AuBuchon P., Cardigan R., Van Der Meer P.F., Murphy S., Prowse C., et al. Storage of platelets in additive solutions: a multicentre study of the in vitro effects of potassium and magnesium. Vox Sang. 2003; 85(3): 199–205. doi:10.1046/j.1423-0410.2003.00356.x.

15. Gupta A., Chandra T., Kumar A. In vitro function of random donor platelets stored for 7 days in composol platelet additive solution. Asian J. Transfus. Sci. 2011; 5(1): 11–4. doi:10.4103/0973-6247.7569.

16. Freedman J., Loscalzo J., Barnard R., Alpert C., Keaney F., Michelson A. Nitric oxide released from activated platelets inhibits platelet recruitment. J. Clin. Invest. 1997; 100(2): 350–6.

17. Manasa K., Vani R. Influence of oxidative stress on stored platelets. Adv. Hematol. 2016; (2016): 4091461. doi:10.1155/2016/4091461.


Review

For citations:


Azimova M.Kh., Galstyan G.M., Gaponova T.V., Karyakin A.V., Kryukova G.N., Nekhaevskaya S.S., Skotselyas E.D., Flegontov P.A. BIOCHEMICAL PARAMETERS OF DONOR PLATELET CONCENTRATES DURING THE STORAGE AFTER PATHOGEN INACTIVATION WITH THE AID OF TECHNOLOGY “AMOTOSALEN + ULTRA-VIOLET A IRRADIATION” IN VITRO. Russian journal of hematology and transfusiology. 2017;62(1):37-40. (In Russ.) https://doi.org/10.18821/0234-5730-2017-62-1-37-40

Views: 551


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 0234-5730 (Print)
ISSN 2411-3042 (Online)